Dr. Samer Al Hadidi treats patients with myeloma and different plasma compartment disorders. He joined the University of Arkansas for Medical Science’s Myeloma Center successful the Winthrop P. Rockefeller Cancer Institute successful 2022 and besides serves arsenic an adjunct prof successful the UAMS College of Medicine’s Department of Hematology and Oncology.
Al Hadidi completed his fellowship successful hematology/oncology from Baylor College of Medicine successful Houston, wherever helium focused connected compartment and cistron therapy. He completed his residency successful interior medicine astatine Michigan State University successful Flint and received a master’s grade successful objective probe and statistical investigation from the University of Michigan successful Ann Arbor. He received his aesculapian grade from the University of Jordanin Amman.
While successful grooming successful Flint, Michigan, helium encountered galore patients with constricted resources, which affected their entree to therapy and treatment. He has focused connected studying and researching wellness disparities among Black patients and different minorities for the past six years.
Al Hadidi and his colleagues precocious published, “Geographic and Racial Disparities successful Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple Myeloma” successful JAMA Network Open. They examined whether determination is equitable geographic entree to chimeric antigen receptor T cells (CAR-T) and bispecific antibodies trials for patients with myeloma successful the United States. This is important due to the fact that galore patients with myeloma are Black.
Findings from this cross-sectional survey of information from 69 objective trials successful the United States showed that 34% of the states analyzed had nary CAR-T oregon bispecific objective proceedings openings and that determination are constricted unfastened sites successful states with the highest percentages of Black residents. These results suggest that the existent CAR-T and bispecific antibodies trials for myeloma bash not connection equitable entree for Black patients.
This is conscionable the latest of galore examples of Al Hadidi’s probe focusing connected wellness equity among minorities. Blacks individuals are astatine much than doubly the hazard of processing myeloma and much apt to person a diagnosis astatine a younger age.
Long earlier this study, Al Hadidi was an writer connected papers of population-based probe connected the wellness disparities that Black and Hispanic patients with myeloma person experienced pursuing their diagnoses. He has besides studied and written astir the existent challenges to having Black patients with myeloma enactment successful crab objective trials, noting that radical disparities persist successful the attraction of and outcomes for number patients, and helium has projected solutions for the issue.
In 2021, Dr. Al Hadidi chaired and moderated the American Society of Hematology Diversity and Equity Poster Walk and held respective interviews discussing radical disparities successful myeloma treatment, including that Black patients are underrepresented successful CAR-T trials.
Here are immoderate of papers that Al Hadidi co-authored and media sum connected the studies:
- “Enrollment of achromatic participants successful pivotal objective trials supporting america nutrient and cause medication support of chimeric antigen receptor–t compartment therapy for hematological malignant neoplasms.” Published successful Jama Network Open, April 2022.
- “Health disparities experienced by Black and Hispanic Americans with aggregate myeloma successful the United States: a population-based study.” Published successful Leukemia & Lymphoma successful December 2021.
- “Participation of Black Americans successful crab objective trials: existent challenges and projected solutions.” Published successful JCO Oncology Practice successful May 2021.
- “Participation of African American persons successful objective trials supporting U.S. Food and Drug Administration support of crab drugs.” Published successful Annals of Internal Medicine successful August 2020.
- Study finds ‘substantial’ underrepresentation of Black patients successful CAR-T objective trials. May 2022, healio.com
- Dearth of information from achromatic patients noted successful CAR T objective trials supporting FDA approvals. May 2022, cancernetwork.com
- Racial disparities persist successful aggregate myeloma care, outcomes. July 2021, medicalxpress.com
- African Americans underrepresented successful crab trials that led to FDA approvals. June 2020, healio.com)
- Black Americans are inactive dying of crab astatine the highest rates. September 2020, nbcnews.com
- Study: Black patients underrepresented successful pivotal CAR T-cell trials. April 2022, raps.org
For much quality connected crab updates, probe and education, don’t hide to subscribe to CURE®’s newsletters here.
English (US)